Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication
- PMID: 33593396
- PMCID: PMC7888169
- DOI: 10.1186/s12943-021-01309-7
Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication
Abstract
Early detection and diagnosis are the key to successful clinical management of pancreatic cancer and improve the patient outcome. However, due to the absence of early symptoms and the aggressiveness of pancreatic cancer, its 5-year survival rate remains below 5 %. Compared to tissue samples, liquid biopsies are of particular interest in clinical settings with respect to minimal invasiveness, repeated sampling, complete representation of the entire or multi-site tumor bulks. The potential of liquid biopsies in pancreatic cancer has been demonstrated by many studies which prove that liquid biopsies are able to detect early emergency of pancreatic cancer cells, residual disease, and recurrence. More interestingly, they show potential to delineate the heterogeneity, spatial and temporal, of pancreatic cancer. However, the performance of liquid biopsies for the diagnosis varies largely across different studies depending of the technique employed and also the type and stage of the tumor. One approach to improve the detect performance of liquid biopsies is to intensively inspect circulome and to define integrated biomarkers which simultaneously profile circulating tumor cells and DNA, extracellular vesicles, and circulating DNA, or cell free DNA and proteins. Moreover, the diagnostic validity and accuracy of liquid biopsies still need to be comprehensively demonstrated and validated.
Keywords: Bioinformatics; Circulome; Diagnosis; Liquid biopsy; Pancreatic cancer; Prognosis.
Conflict of interest statement
No, authors declare no competing interests.
Figures

Similar articles
-
Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer.World J Gastroenterol. 2016 Oct 14;22(38):8480-8488. doi: 10.3748/wjg.v22.i38.8480. World J Gastroenterol. 2016. PMID: 27784960 Free PMC article. Review.
-
Liquid biopsies for management of pancreatic cancer.Transl Res. 2018 Nov;201:98-127. doi: 10.1016/j.trsl.2018.07.008. Epub 2018 Jul 26. Transl Res. 2018. PMID: 30118658 Review.
-
Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA.Mol Oncol. 2019 Aug;13(8):1623-1650. doi: 10.1002/1878-0261.12537. Epub 2019 Jul 30. Mol Oncol. 2019. PMID: 31243883 Free PMC article. Review.
-
Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis.Theranostics. 2020 Mar 15;10(10):4544-4556. doi: 10.7150/thno.40532. eCollection 2020. Theranostics. 2020. PMID: 32292514 Free PMC article. Review.
-
Liquid biopsy in pancreatic cancer - Current perspective and future outlook.Biochim Biophys Acta Rev Cancer. 2023 May;1878(3):188868. doi: 10.1016/j.bbcan.2023.188868. Epub 2023 Feb 24. Biochim Biophys Acta Rev Cancer. 2023. PMID: 36842769 Review.
Cited by
-
CTC, ctDNA, and Exosome in Thyroid Cancers: A Review.Int J Mol Sci. 2023 Sep 6;24(18):13767. doi: 10.3390/ijms241813767. Int J Mol Sci. 2023. PMID: 37762070 Free PMC article. Review.
-
Screening and Validation of Independent Predictors of Poor Survival in Pancreatic Cancer.Pathol Oncol Res. 2021 Jul 12;27:1609868. doi: 10.3389/pore.2021.1609868. eCollection 2021. Pathol Oncol Res. 2021. PMID: 34321959 Free PMC article.
-
Clinical bioinformatics desiderata for molecular tumor boards.Brief Bioinform. 2024 Jul 25;25(5):bbae447. doi: 10.1093/bib/bbae447. Brief Bioinform. 2024. PMID: 39297878 Free PMC article. Review.
-
Comparison of different Pancreatic cancer treatments: a three-year retrospective study in the oncology center of Tangier university hospital, Morocco.BMC Gastroenterol. 2023 Dec 21;23(1):452. doi: 10.1186/s12876-023-03071-0. BMC Gastroenterol. 2023. PMID: 38129797 Free PMC article.
-
Overexpression of BCL2, BCL6, VEGFR1 and TWIST1 in Circulating Tumor Cells Derived from Patients with DLBCL Decreases Event-Free Survival.Onco Targets Ther. 2022 Dec 30;15:1583-1595. doi: 10.2147/OTT.S386562. eCollection 2022. Onco Targets Ther. 2022. PMID: 36606244 Free PMC article.
References
-
- Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15:333–48. - PubMed
-
- Yoshinaga S, Suzuki H, Oda I, Saito Y. Role of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for diagnosis of solid pancreatic masses. Dig Endosc. John Wiley & Sons, Ltd; 2011;23:29–33. - PubMed
-
- Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388:73–85. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical